Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16131583 | 1.00 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL13708338 | 1.00 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL16131584 | 1.00 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL1592238 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL12724710 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL12724712 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL16131582 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL12724709 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL13708353 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA | |
| SCHEMBL1592253 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1CES2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2011-04-21 | — | — | US | disclosed |
| WO-2009115927-A2 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | NUDT1, NT5C3B, NTPCR | ALDH1A1 2724/4885NPC1 217/4885CES2 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.